Stock CLDI CALIDI BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Real-time Estimate Cboe BZX
Other stock markets
 10:21:18 2024-07-09 am EDT 		5-day change 1st Jan Change
0.152 USD -6.23% Intraday chart for Calidi Biotherapeutics, Inc. -23.91% -89.80%
Jul. 05 Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split MT
Jul. 02 Calidi Biotherapeutics, Inc. announced that it has received $0.6 million in funding CI

Evolution of the average Target Price on Calidi Biotherapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c35b3a74f4868b87131e5d.VfnmSctG8AIxItsmgA8q2o_R3sBhxvSvqxRSeELQQKk.HbulE_IKlnNwR61txjlJvMrm540MhZD6nUATGxWiD-ZizIkRqjKyTAVvqA~4b31a4243ce7e9b9f7310acbbad6dc26

Analyst Recommendations on Calidi Biotherapeutics, Inc.

Ladenburg Thalmann Initiates Calidi Biotherapeutics at Buy MT
Calidi Biotherapeutics Prices $6.1 Million Offering MT
H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating MT
HC Wainwright Starts Calidi Biotherapeutics With Buy Rating, $11 Price Target MT
Baird Starts Calidi Biotherapeutics With Outperform Rating, Price Target is $9 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1621 USD
Average target price
1.5 USD
Spread / Average Target
+825.35%
High Price Target
2 USD
Spread / Highest target
+1,133.81%
Low Price Target
1 USD
Spread / Lowest Target
+516.90%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Calidi Biotherapeutics, Inc.

HC Wainwright
Baird

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CLDI Stock
  4. Consensus Calidi Biotherapeutics, Inc.